Press Releases

Printer Friendly Version View printer-friendly version
<< Back
Download PDF Download PDF
Vitae Pharmaceuticals is named one of the Top Ten Best Places to Work by The Scientist magazine

Fort Washington, PA, April 28, 2011 – Vitae Pharmaceuticals announced today that the Company is ranked #6 in The Scientist magazine’s "Best Places to Work in Industry" ninth annual survey. Survey respondents were asked to assess their working environment according to 43 criteria in eight different categories, including Research Environment, Integrity, Job Satisfaction, and Training and Development. Survey respondents cited the research environment and company management at Vitae as leading reasons for their positive work experiences.

Vitae President and CEO Jeffrey Hatfield commented, “At Vitae, all of our team members – experts in medicinal and computational chemistry, biology, translational medicine, information technology and business – have together created a dynamic, entrepreneurial and highly integrated culture of research excellence. We are dedicated to discovering and advancing solutions to some of the world’s most significant diseases, including chronic kidney disease, diabetes, Alzheimer disease and atherosclerosis. We are proud of the rapid progress we have already accomplished, and look forward to making an impact in the lives of patients around the globe with our discoveries.”

The full article with detailed survey results can be found in the May issue of The Scientist and is available online at: http://www.the‐scientist.com/bptw/.

About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical‐stage biopharmaceutical company building a portfolio of novel, small molecule, best‐in‐class compounds that address large markets, including chronic kidney disease, diabetes, Alzheimer’s disease and atherosclerosis. Vitae’s lead compound, VTP‐27999, is a wholly owned, novel, potent and selective renin inhibitor designed to offer a best‐in‐class therapeutic profile and, most importantly, improved kidney protection versus other marketed agents. Vitae Pharmaceuticals expects to move VTP‐27999 into Phase 2b studies around the end of 2011.

Vitae is expert in structure‐based drug discovery and combines a proprietary technical platform with the experience and insight of world class scientists to advance best‐in‐class compounds for high value, hard‐to‐drug targets. Vitae’s proprietary, discovery platform has clear advantages in creating and analyzing novel drug candidates that meet pre‐defined physicochemical characteristics. The accuracy and speed of this system has enabled Vitae to solve challenging targets in multiple therapeutic areas – discovering and advancing attractive compounds in a rapid and highly capital efficient manner. Vitae Pharmaceuticals is financed by leading corporate and venture capital investors; its last venture round was in 2004.

Vitae’s 45 scientists are located in Fort Washington, Pennsylvania. For additional information, please visit the company’s website, www.vitaepharma.com.

Contacts:
Burns McClellan on behalf of Vitae
Justin Jackson, Maroussia Czarny (media),
212‐213‐0006
jjackson@burnsmc.com
mczarny@burnsmc.com